Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02298634
Other study ID # BFD 06-2018
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date August 20, 2018
Est. completion date February 28, 2021

Study information

Verified date February 2023
Source CENTOGENE GmbH Rostock
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood


Description:

Farber disease (FD), also known as Farber's lipogranulomatosis, is an autosomal recessive lysosomal storage disease marked by a deficiency in enzyme ceramidase which causes a progressive accumulation of fatty material lipids leading to abnormalities in the joints, liver, throat, tissues and central nervous system. FD is an extremely rare disorder, with a prevalence of less than 1/1000000. Currently only about 80 cases are reported worldwide. Disease onset is typically in early infancy but may occur later in life. FD is caused by a mutation in the ASAH1 gene, situated on the short arm of chromosome 8. This gene codes for acid ceramidase, a lysosomal heterodimeric enzyme that hydrolyzes ceramide into sphingosine and fatty acid. To date, less than 25 distinct mutations have been identified in Farber patients, but no large deletions have yet been reported. It is inherited with an autosomal recessive pattern. The clinical presentation of FD is characterized by the appearance of subcutaneous skin nodules, ordinarily near the joints, most often interphalangeal, wrist, elbow and ankle joints, or over points of mechanical pressure. These manifestations are very painful and lead to progressive joint stiffness, limitation of motion by contractures and finally to immobilization and deformation of joints. Also, a characteristic sign of FD is the development of a progressive hoarseness due to laryngeal involvement. Beside these major manifestations seven phenotypes have been described which differ in severity and additional organ involvement, like the lungs, nervous system, heart and lymph nodes. Dependent on residual lysosomal ceramidase turnover, patients have a variable degree of central nervous system disease, leading to progressive neurologic deterioration. In most cases the neuronal dysfunction rather than the general physical dystrophy seems to limit the duration of FD. As well, patients with FD may die due to pulmonary disease with interstitial pneumonia. First symptoms usually appear between the newborn period and the first birthday. Milder forms of type 3 were described with onset at 20 months of age. Clinical manifestation in type 5 of FD, dominated by neurologic deterioration, begins at 1 to 2 1/2 years of life. Patients mainly die within the first years of life, but prolonged courses in patients without severe nervous disease may also be observed. Type 1 is the most common or classical form of this condition and is associated with the classic signs of voice, skin, and joint problems that begin a few months after birth. Developmental delay and lung disease also commonly occur. Infants born with type 1 FD usually survive only into early childhood. Types 2 and 3 generally have less severe signs and symptoms than the other types. Affected individuals have the three classic signs and usually do not have developmental delay. Children with these types of FD typically live into mid- to late childhood. Types 4 and 5 are associated with severe neurological problems. Type 4 usually causes life-threatening health problems beginning in infancy due to massive lipid deposits in the liver, spleen, lungs, and immune system tissues. Children with this type typically do not survive past their first year of life. Type 5 is characterized by progressive decline in brain and spinal cord (central nervous system) function, which causes paralysis of the arms and legs (quadriplegia), seizures, loss of speech, involuntary muscle jerks (myoclonus), and developmental delay. Children with type 5 FD survive into early childhood. Types 6 and 7 are very rare, and affected individuals have other associated disorders in addition to FD. New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity. Therefore it is the goal of the study to identify and validate a new biochemical marker from the blood of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 28, 2021
Est. primary completion date February 28, 2021
Accepts healthy volunteers No
Gender All
Age group 2 Months and older
Eligibility INCLUSION CRITERIA - Informed consent will be obtained from the parents before any study related procedures. - Patients of both gender older than 2 months - The patient has a diagnosis of Farber disease or a high-grade suspicion for Farber disease - High-grade suspicion present, if one or more inclusion criteria are valid: 1. - Positive family anamnesis for Farber disease 2. - Hoarse cry due to laryngeal involvement 3. - Dysostosis multiplex 4. - Painful swollen joints, 5. - Arthritis 6. - Hepatomegaly 7. - Splenomegaly 8. - Elevated urine ceramide levels 9. - Histiocytic infiltration of liver, spleen, and lungs 10. - Ceramidase deficiency EXCLUSION CRITERIA - No Informed consent from the parents before any study related procedures. - Patients of both gender younger than 2 months - No diagnosis of Farber disease or no valid criteria for profound suspicion of Farber disease

Study Design


Locations

Country Name City State
Egypt Children Hospital, Faculty of Medicine, Cairo University Cairo
Germany Centogene AG Rostock
India Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN) Mumbai

Sponsors (1)

Lead Sponsor Collaborator
CENTOGENE GmbH Rostock

Countries where clinical trial is conducted

Egypt,  Germany,  India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sequencing of the Farber disease related gene Next-Generation Sequencing (NGS) of the ASAH1 gene will be performed. The mutation will be confirmed by Sanger sequencing. 4 weeks
Secondary The Farber disease specific biomarker candidates finding The quantitative determination of small molecules (molecular weight 150-700 kD, given as ng/µl) within a dried blood spot sample will be validated via liquid chromatography multiple reaction-monitoring mass spectrometry (LC/MRM-MS) and compared with a merged control cohort. The statistically best validated molecule will be considered as a disease specific biomarker. 24 months
See also
  Status Clinical Trial Phase
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Not yet recruiting NCT06345495 - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Phase 2
Completed NCT04430881 - A National Study in Patients With Unexplained Splenomegaly
Completed NCT01948076 - Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination N/A
Completed NCT04716166 - Incentive Spirometry and Upper Abdominal Laparoscopic Surgery N/A
Completed NCT01907932 - Estimation of Spleen by Residents With VScan N/A
Recruiting NCT03801434 - Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Phase 2
Terminated NCT02421354 - Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis Phase 2
Recruiting NCT05641103 - PREDIGA 2: Spanish Acronym of "Educational and Diagnostic Project for Gaucher and ASMD"
Completed NCT01810419 - Ultrasound Estimation of Spleen Size N/A
Recruiting NCT01201655 - Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis N/A
Active, not recruiting NCT02871219 - Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma Phase 2
Completed NCT00006148 - Spleen Size in Peripheral Blood Stem Cell Donors N/A
Withdrawn NCT02298699 - Biomarker for Sly Disease (MPS VII) (BioSly)
Withdrawn NCT01331642 - Biomarker for Gaucher Disease: BioGaucher (BioGaucher)
Terminated NCT02730884 - Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Phase 2
Terminated NCT02463669 - The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department